[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:msln-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"MSLN Gene",5,[7,15,21,27,34],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06623396","A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer",[11],"Phase 1","RECRUITING","2026-08-26T02:18:03.638950Z","2026-05-05T02:43:28.125590Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06885697","Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",[11],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.985101Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06756035","CT-95 in Advanced Cancers Associated With Mesothelin Expression",[11],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:28.867277Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":32,"content_modified":33},"NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",[31],"Phase 1\u002FPhase 2","2026-08-26T02:19:12.219640Z","2026-05-05T02:43:26.963212Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT05568680","SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma",[11],"2026-08-26T02:15:31.806698Z","2026-05-05T02:35:31.692599Z"]